Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Merck Frosst reveals discoveries in the field of COX-2 inhibitors at ACS meeting

Sep. 11, 1998

Kotobuki selects development candidate from novel series with selectivity for COX-2

Sep. 11, 1998

Merck's COX-2 inhibitor Vioxx shown safe and effective in clinical trials

Sep. 10, 1998

MMP inhibitor PGE-2946979 shows good oral antiarthritic activity in rats

Sep. 10, 1998

Astra presents data on novel series of cPLA2 inhibitors

Sep. 9, 1998

Enbrel efficacy demonstrated in juvenile RA patients

Sep. 7, 1998

MDX-CD4 development progresses, triggering milestone payment from Eisai

Sep. 7, 1998

Substituted pyrimidines from Amgen inhibit cytokine production

Sep. 7, 1998

Antiadhesion agents prepared and evaluated at Hoechst

Sep. 7, 1998

MMP inhibitors in early development at British Biotech

Sep. 7, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...